Bone Marrow Lymphocyte Populations of Innate Immunity in Breast Cancer Patients

The innate immunity system plays an important role in antitumor protection, and more and more attention has been paid to its study recent years. However, the interrelation of the effect or subpopulations of the cells of the innate immunity in bone marrow with clinical parameters is poorly studied. The paper presents data on the composition of innate immune cells in the bone marrow of 64 patients with operable breast cancer, as well as 10 women with benign processes in the mammary gland. As result a significant correlation between the molecular subtype of cancer and the level of B1- lymphocytes was identified. Breast cancer patients levels of NK cells (CD56 + CD3- and CD16 + CD3-) in the bone marrow were significantly higher in patients with low proliferative activity (Ki-67 less than 20%), compared to patients having a high tumor proliferation index. Populations of NK cells were interrelated with erythropoiesis in patients with breast cancer and were significantly higher in cases of reduced basophilic and polychromatophilicnormoblasts.

Download Full-text

Bone Marrow NK-Cells In Breast Cancer Patients Are Interdependent With Biological Peculiarities Of Tumor And Patient’s Erythropoiesis

Онкогинекология ◽

10.52313/22278710_2019_3_4 ◽

2019 ◽

pp. 4-13

Author(s):

Vanui A. Mkrtchyan ◽

Igor K. Vorotnikov ◽

Olga A. Chernysheva ◽

Alexandra D. Palladina ◽

Nikolay N. Tupitsyn

Keyword(s):

Breast Cancer ◽

Bone Marrow ◽

Nk Cells ◽

Cancer Patients ◽

Breast Cancer Patients

Download Full-text

Prognostic factors associated with pathological complete response in early breast cancer patients undergoing neoadjuvant chemotherapy: The importance of Ki-67 and molecular subtype

Annals of Oncology ◽

10.1093/annonc/mdy270.230 ◽

2018 ◽

Vol 29 ◽

pp. viii75

Author(s):

B.L. Rapoport ◽

J.A. Barnard-Tidy ◽

T. Smit ◽

S.J. Nayler ◽

C.A. Benn

Keyword(s):

Breast Cancer ◽

Prognostic Factors ◽

Neoadjuvant Chemotherapy ◽

Cancer Patients ◽

Pathological Complete Response ◽

Molecular Subtype ◽

Complete Response ◽

Breast Cancer Patients ◽

Ki 67 ◽

Factors Associated

Download Full-text

Abstract P1-15-25: Prognostic factors associated with pathological complete response in early breast cancer patients undergoing neoadjuvant chemotherapy. The importance of Ki-67 and molecular subtype

10.1158/1538-7445.sabcs18-p1-15-25 ◽

2019 ◽

Author(s):

BL Rapoport ◽

J Barnard-Tide ◽

T Smit ◽

S Nayler ◽

C-A Benn

Keyword(s):

Breast Cancer ◽

Prognostic Factors ◽

Neoadjuvant Chemotherapy ◽

Cancer Patients ◽

Pathological Complete Response ◽

Molecular Subtype ◽

Complete Response ◽

Breast Cancer Patients ◽

Ki 67 ◽

Factors Associated

Download Full-text

Can Ki-67 Play a Role in Prediction of Breast Cancer Patients' Response to Neoadjuvant Chemotherapy?

BioMed Research International ◽

10.1155/2014/628217 ◽

2014 ◽

Vol 2014 ◽

pp. 1-7 ◽

Cited By ~ 11

Author(s):

Juhasz-Böss Ingolf ◽

Mavrova Russalina ◽

Moga Simona ◽

Radosa Julia ◽

Schmidt Gilda ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Cancer Patients ◽

Molecular Subtype ◽

Predictive Marker ◽

Chemotherapy Response ◽

Daily Routine ◽

Breast Cancer Patients ◽

Ki 67 ◽

Response To Neoadjuvant Chemotherapy

Background. Currently the choice of breast cancer therapy is based on prognostic factors. The proliferation marker Ki-67 is used increasingly to determine the method of therapy. The current study analyses the predictive value of Ki-67 in foreseeing breast cancer patients’ responses to neoadjuvant chemotherapy.Methods. This study includes patients with invasive breast cancer treated between 2008 and 2013. The clinical response was assessed by correlating Ki-67 to histological examination, mammography, and ultrasonography findings.Results. The average Ki-67 value in our patients collectively (n=77) is 34.9 ± 24.6%. The average Ki-67 value is the highest with 37.4 ± 24.0% in patients with a pCR. The Ki-67 values do not differ significantly among the 3 groups: pCR versus partial pathological response versus stable disease/progress (P=0.896). However, Ki-67 values of patients with luminal, Her2 enriched, and basal-like cancers differed significantly from each other. Furthermore, within the group of luminal tumors Ki-67 values of patients with versus without pCR also differed significantly.Conclusion. Our data shows that the Ki-67 value predicts the response to neoadjuvant chemotherapy as a function of the molecular subtype, reflecting the daily routine concerning Ki-67 and its impressing potential and limitation as a predictive marker for neoadjuvant chemotherapy response.

Download Full-text